146 related articles for article (PubMed ID: 23867347)
41. Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease.
Breccia M; Lo-Coco F
Expert Opin Pharmacother; 2012 May; 13(7):1031-43. PubMed ID: 22468778
[TBL] [Abstract][Full Text] [Related]
42. Arsenic trioxide: an ancient drug revived.
Zhou J
Chin Med J (Engl); 2012 Oct; 125(19):3556-60. PubMed ID: 23044323
[TBL] [Abstract][Full Text] [Related]
43. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P
Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811
[TBL] [Abstract][Full Text] [Related]
44. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia.
Ghavamzadeh A; Alimoghaddam K; Rostami S; Ghaffari SH; Jahani M; Iravani M; Mousavi SA; Bahar B; Jalili M
J Clin Oncol; 2011 Jul; 29(20):2753-7. PubMed ID: 21646615
[TBL] [Abstract][Full Text] [Related]
45. Real-life experience of a brief arsenic trioxide-based consolidation chemotherapy in the management of acute promyelocytic leukemia: favorable outcomes with limited anthracycline exposure and shorter consolidation therapy.
Leech M; Morris L; Stewart M; Smith BD; Bashey A; Holland K; Solomon S; Zhang X; Carraway HE; Pratz K; Gore SD; Zeidan AM
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):292-7. PubMed ID: 25499624
[TBL] [Abstract][Full Text] [Related]
46. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
47. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia.
Chen L; Wang J; Hu X; Xu X
Hematology; 2014 Jun; 19(4):202-7. PubMed ID: 24074286
[TBL] [Abstract][Full Text] [Related]
48. Expression of hedgehog proteins in the human thymus.
Sacedón R; Varas A; Hernández-López C; Gutiérrez-deFrías C; Crompton T; Zapata AG; Vicente A
J Histochem Cytochem; 2003 Nov; 51(11):1557-66. PubMed ID: 14566027
[TBL] [Abstract][Full Text] [Related]
49. Signal transduction pathways and transcription factors triggered by arsenic trioxide in leukemia cells.
Sumi D; Shinkai Y; Kumagai Y
Toxicol Appl Pharmacol; 2010 May; 244(3):385-92. PubMed ID: 20193703
[TBL] [Abstract][Full Text] [Related]
50. Identifying arsenic trioxide (ATO) functions in leukemia cells by using time series gene expression profiles.
Yang H; Lin S; Cui J
Gene; 2014 Feb; 535(2):312-7. PubMed ID: 24262935
[TBL] [Abstract][Full Text] [Related]
51. Hypoxia activates the hedgehog signaling pathway in a ligand-independent manner by upregulation of Smo transcription in pancreatic cancer.
Onishi H; Kai M; Odate S; Iwasaki H; Morifuji Y; Ogino T; Morisaki T; Nakashima Y; Katano M
Cancer Sci; 2011 Jun; 102(6):1144-50. PubMed ID: 21338440
[TBL] [Abstract][Full Text] [Related]
52. In the war against solid tumors arsenic trioxide needs partners.
Subbarayan PR; Ardalan B
J Gastrointest Cancer; 2014 Sep; 45(3):363-71. PubMed ID: 24825822
[TBL] [Abstract][Full Text] [Related]
53. Role of Signal Regulatory Protein α in Arsenic Trioxide-induced Promyelocytic Leukemia Cell Apoptosis.
Pan C; Zhu D; Zhuo J; Li L; Wang D; Zhang CY; Liu Y; Zen K
Sci Rep; 2016 Mar; 6():23710. PubMed ID: 27010069
[TBL] [Abstract][Full Text] [Related]
54. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists.
Kim J; Aftab BT; Tang JY; Kim D; Lee AH; Rezaee M; Kim J; Chen B; King EM; Borodovsky A; Riggins GJ; Epstein EH; Beachy PA; Rudin CM
Cancer Cell; 2013 Jan; 23(1):23-34. PubMed ID: 23291299
[TBL] [Abstract][Full Text] [Related]
55. [Clinical study on the fibrinolytic activity in patients with acute promyelocytic leukemia].
Liu YH; Wang ZY; Zhang W; Dai L; Shen WH; Ruan CG
Zhonghua Xue Ye Xue Za Zhi; 2009 Mar; 30(3):145-9. PubMed ID: 19642359
[TBL] [Abstract][Full Text] [Related]
56. Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: a report from the Children's Oncology Group.
Pressey JG; Anderson JR; Crossman DK; Lynch JC; Barr FG
Pediatr Blood Cancer; 2011 Dec; 57(6):930-8. PubMed ID: 21618411
[TBL] [Abstract][Full Text] [Related]
57. Melarsomine suppresses canine osteosarcoma cell survival via inhibition of Hedgehog-GLI signaling.
Nam A; Kim T; Li Q; Rebhun RB; Youn HY; Seo KW
J Vet Med Sci; 2019 Dec; 81(12):1722-1729. PubMed ID: 31645504
[TBL] [Abstract][Full Text] [Related]
58. Morphological differences of primary cilia between human induced pluripotent stem cells and their parental somatic cells.
Nathwani BB; Miller CH; Yang TL; Solimano JL; Liao JC
Stem Cells Dev; 2014 Jan; 23(2):115-23. PubMed ID: 24007236
[TBL] [Abstract][Full Text] [Related]
59. Arsenic trioxide in pediatric cancer - a case series and review of literature.
Abele M; Müller SL; Schleicher S; Hartmann U; Döring M; Queudeville M; Lang P; Handgretinger R; Ebinger M
Pediatr Hematol Oncol; 2021 Aug; 38(5):471-485. PubMed ID: 33635158
[TBL] [Abstract][Full Text] [Related]
60. Activation of the basal cell carcinoma pathway in a patient with CNS HGNET-BCOR diagnosis: consequences for personalized targeted therapy.
Paret C; Theruvath J; Russo A; Kron B; El Malki K; Lehmann N; Wingerter A; Neu MA; Gerhold-Ay A; Wagner W; Sommer C; Pietsch T; Seidmann L; Faber J
Oncotarget; 2016 Dec; 7(50):83378-83391. PubMed ID: 27825128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
